Journal article
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
- Abstract:
-
Background: The multi-centre two-stage SCALOP-2 trial (ISRCTN50083238) assessed whether dose escalation of consolidative chemoradiotherapy (CRT) or concurrent sensitization using the protease inhibitor nelfinavir improve outcomes in locally advanced pancreatic cancer (LAPC) following four cycles of gemcitabine/nab-paclitaxel.
Methods: In stage 1, the maximum tolerated dose (MTD) of nelfinavir concurrent with standard-dose CRT (50.4 Gy in 28 fra...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Elsevier
- Journal:
- European Journal of Cancer More from this journal
- Volume:
- 209
- Article number:
- 114236
- Place of publication:
- England
- Publication date:
- 2024-07-23
- Acceptance date:
- 2024-07-16
- DOI:
- EISSN:
-
1879-0852
- ISSN:
-
0959-8049
- Pmid:
-
39059185
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
2018291
- Local pid:
-
pubs:2018291
- Deposit date:
-
2024-07-29
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2024
- Rights statement:
- © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record